Karen Foster Sells 519 Shares of BioLife Solutions (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) insider Karen Foster sold 519 shares of the firm’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $25.13, for a total value of $13,042.47. Following the completion of the sale, the insider directly owned 192,319 shares in the company, valued at approximately $4,832,976.47. This represents a 0.27% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

BioLife Solutions Stock Performance

Shares of BioLife Solutions stock traded up $0.40 during trading on Wednesday, reaching $25.01. 296,709 shares of the company’s stock were exchanged, compared to its average volume of 445,500. BioLife Solutions, Inc. has a 1-year low of $19.10 and a 1-year high of $29.62. The company has a market cap of $1.20 billion, a P/E ratio of -357.23 and a beta of 1.93. The firm’s 50-day moving average price is $26.39 and its 200 day moving average price is $24.51.

Analyst Ratings Changes

BLFS has been the subject of a number of research reports. Wall Street Zen cut shares of BioLife Solutions from a “buy” rating to a “hold” rating in a report on Sunday, November 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of BioLife Solutions in a research note on Wednesday, October 8th. Zacks Research lowered shares of BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 8th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $32.00 target price on shares of BioLife Solutions in a research note on Monday, November 24th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $30.75.

Institutional Investors Weigh In On BioLife Solutions

Hedge funds have recently added to or reduced their stakes in the business. Amalgamated Bank grew its holdings in BioLife Solutions by 3.5% during the 3rd quarter. Amalgamated Bank now owns 10,898 shares of the medical equipment provider’s stock worth $278,000 after acquiring an additional 366 shares during the last quarter. Ameritas Investment Partners Inc. grew its stake in shares of BioLife Solutions by 12.8% in the second quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider’s stock worth $83,000 after purchasing an additional 441 shares during the last quarter. Louisiana State Employees Retirement System increased its holdings in BioLife Solutions by 2.9% in the third quarter. Louisiana State Employees Retirement System now owns 17,800 shares of the medical equipment provider’s stock valued at $454,000 after purchasing an additional 500 shares during the period. Isthmus Partners LLC increased its holdings in BioLife Solutions by 0.4% in the second quarter. Isthmus Partners LLC now owns 132,125 shares of the medical equipment provider’s stock valued at $2,846,000 after purchasing an additional 509 shares during the period. Finally, The Manufacturers Life Insurance Company raised its position in BioLife Solutions by 2.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,764 shares of the medical equipment provider’s stock worth $447,000 after purchasing an additional 555 shares during the last quarter. 93.24% of the stock is currently owned by institutional investors and hedge funds.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.